Literature DB >> 1402685

Inhibition or activation of human T cell receptor transfectants is controlled by defined, soluble antigen arrays.

D E Symer1, R Z Dintzis, D J Diamond, H M Dintzis.   

Abstract

We present evidence that direct T cell receptor (TCR) occupancy by antigen can either activate or inhibit T cells, depending upon whether or not a threshold number of local TCRs are crosslinked by multivalent arrays of the antigen. Variants of Jurkat cells were previously transfected with TCR alpha and beta chains that bind fluorescein, yielding FL-TCR+ human T cells. The transfectants are activated upon binding soluble multivalent antigen arrays at concentrations well below those required for monovalent interactions. This activation, measured by calcium fluxes and interleukin 2 (IL-2) production, indicates the superior binding avidity of multivalent ligands. Smaller, less multivalent arrays do not activate the cells, but antagonize larger arrays, demonstrating that antigen can bind TCR as either agonist or antagonist. The balance between activation and inhibition depends upon antigen array size, ligand valence, and concentration, indicating that a threshold extent of receptor crosslinking, and not individual perturbations of single TCR, is required for activation by antigen. Approximately 100 stimulatory arrays specifically bind per FL-TCR+ cell at concentrations where IL-2 production is half-maximal.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1402685      PMCID: PMC2119418          DOI: 10.1084/jem.176.5.1421

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  50 in total

1.  Activation of Src-like protein-tyrosine kinase Lyn and its association with phosphatidylinositol 3-kinase upon B-cell antigen receptor-mediated signaling.

Authors:  Y Yamanashi; Y Fukui; B Wongsasant; Y Kinoshita; Y Ichimori; K Toyoshima; T Yamamoto
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-01       Impact factor: 11.205

2.  Structural evidence for induced fit as a mechanism for antibody-antigen recognition.

Authors:  J M Rini; U Schulze-Gahmen; I A Wilson
Journal:  Science       Date:  1992-02-21       Impact factor: 47.728

3.  T-cell receptors. At grips with interactions.

Authors:  A F Williams; A D Beyers
Journal:  Nature       Date:  1992-04-30       Impact factor: 49.962

Review 4.  Transgenic mice and analysis of B-cell tolerance.

Authors:  C C Goodnow
Journal:  Annu Rev Immunol       Date:  1992       Impact factor: 28.527

5.  Contingent genetic regulatory events in T lymphocyte activation.

Authors:  G R Crabtree
Journal:  Science       Date:  1989-01-20       Impact factor: 47.728

6.  Structure of an antibody-antigen complex: crystal structure of the HyHEL-10 Fab-lysozyme complex.

Authors:  E A Padlan; E W Silverton; S Sheriff; G H Cohen; S J Smith-Gill; D R Davies
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

7.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

8.  Increases in tyrosine phosphorylation are detectable before phospholipase C activation after T cell receptor stimulation.

Authors:  C H June; M C Fletcher; J A Ledbetter; L E Samelson
Journal:  J Immunol       Date:  1990-03-01       Impact factor: 5.422

9.  The accessory function of murine intercellular adhesion molecule-1 in T lymphocyte activation. Contributions of adhesion and co-activation.

Authors:  P Kuhlman; V T Moy; B A Lollo; A A Brian
Journal:  J Immunol       Date:  1991-03-15       Impact factor: 5.422

10.  Expression of T cell antigen receptor heterodimers in a lipid-linked form.

Authors:  A Y Lin; B Devaux; A Green; C Sagerström; J F Elliott; M M Davis
Journal:  Science       Date:  1990-08-10       Impact factor: 47.728

View more
  11 in total

1.  Kinetic discrimination in T-cell activation.

Authors:  J D Rabinowitz; C Beeson; D S Lyons; M M Davis; H M McConnell
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-20       Impact factor: 11.205

2.  The SCHOOL of nature: I. Transmembrane signaling.

Authors:  Alexander B Sigalov
Journal:  Self Nonself       Date:  2010-01

3.  The SCHOOL of nature: III. From mechanistic understanding to novel therapies.

Authors:  Alexander B Sigalov
Journal:  Self Nonself       Date:  2010-06-11

4.  Superactivation of an immune response triggered by oligomerized T cell epitopes.

Authors:  O Rötzschke; K Falk; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

5.  Multivalent Soluble Antigen Arrays Exhibit High Avidity Binding and Modulation of B Cell Receptor-Mediated Signaling to Drive Efficacy against Experimental Autoimmune Encephalomyelitis.

Authors:  Brittany L Hartwell; Chad J Pickens; Martin Leon; Cory Berkland
Journal:  Biomacromolecules       Date:  2017-05-17       Impact factor: 6.988

Review 6.  Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics.

Authors:  Chuda Chittasupho; Teruna J Siahaan; Charlotte M Vines; Cory Berkland
Journal:  Ther Deliv       Date:  2011-07

7.  TCR Signaling Emerges from the Sum of Many Parts.

Authors:  Michael S Kuhns; Mark M Davis
Journal:  Front Immunol       Date:  2012-06-25       Impact factor: 7.561

8.  Comparison of peptides bound to spleen and thymus class II.

Authors:  P Marrack; L Ignatowicz; J W Kappler; J Boymel; J H Freed
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307

9.  Dimerization of soluble major histocompatibility complex-peptide complexes is sufficient for activation of T cell hybridoma and induction of unresponsiveness.

Authors:  J P Abastado; Y C Lone; A Casrouge; G Boulot; P Kourilsky
Journal:  J Exp Med       Date:  1995-08-01       Impact factor: 14.307

10.  Potent T cell activation with dimeric peptide-major histocompatibility complex class II ligand: the role of CD4 coreceptor.

Authors:  A R Hamad; S M O'Herrin; M S Lebowitz; A Srikrishnan; J Bieler; J Schneck; D Pardoll
Journal:  J Exp Med       Date:  1998-11-02       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.